Neurophysiological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain disruption chemotherapy.
Watts
C
C
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001932:Brain Neoplasms / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications*; D008223:Lymphoma / Q000188:drug therapy*; D009460:Neurologic Examination / Q000187:drug effects*
D000970:Antineoplastic Agents